01
Fortified Tumors
Build Barriers
Like medieval fortresses, solid tumors build protective walls that shield cancer cells from the immune system.
The Missing Link In
PushCART is transforming the face of cellular immunotherapy therapy for solid tumors.
While CAR-T has been successful for liquid tumors (leukemias/lymphomas/myelomas) it has not proved effective in the solid tumors that comprise 90% of all cancers (breast, lung, colorectal, pancreatic, ovarian, etc.).
(About Us)
Our mission is to make cellular immunotherapy safe and effective at treating solid tumor cancers.
PushCART Therapeutics is pioneering a new generation of cellular immunotherapies designed to overcome one of cancer's greatest defenses.
Our proprietary enzyme-enabled technology empowers immune cells to penetrate solid tumors, unlocking the potential of cell therapies for the cancers that represent nearly 90% of all cancer diagnoses.
Like medieval fortresses, solid tumors build protective walls that shield cancer cells from the immune system.
PushCART provides the "battering ram," using engineered enzymes to break down the tumor's protective matrix
Once inside, immune cells can work more effectively, complementing a broad range of existing cancer therapies.
Addresses one of the biggest barriers in cellular immunotherapy, enabling immune cells to reach solid tumors.
Uses engineered enzymes to degrade the tumor's protective extracellular matrix.
Enhances the effectiveness of existing cell therapies by improving tumor penetration.
